癌症生物疗法市场规模、份额和成长分析（治疗方法、癌症类型、给药途径、分销管道和地区划分）—2026-2033年产业预测

预计到 2024 年，全球癌症生物疗法市场规模将达到 1,085 亿美元，到 2025 年将达到 1,164.2 亿美元，到 2033 年将达到 2045.6 亿美元，预测期（2026-2033 年）的复合年增长率为 7.3%。

由于癌症发病率不断上升以及专业治疗机构的激增，全球生物癌症疗法市场预计将显着扩张。专家正利用奈米技术开发先进的治疗方案，为个人化癌症治疗创造可能。对生物疗法的关注以及奈米技术的融合有望变革癌症治疗，使每位患者都能获得更个人化和有效的治疗效果。随着该领域持续的研发和技术进步，生物癌症疗法市场预计将迎来显着成长，从而加强对抗癌症的斗争，并有助于改善全球整体。

全球癌症生物製剂治疗市场驱动因素

全球癌症发生率的不断上升是推动全球癌症生物製剂市场扩张的主要动力。尤其值得注意的是，小细胞肺癌（SCLC）病例的增加，这种癌症主要影响60至80岁的人，已成为一项紧迫的医疗挑战。 SCLC的高死亡率以及肺癌作为癌症相关死亡的主要原因，进一步凸显了创新治疗方法的紧迫性。这些因素推动了对癌症生物製剂的需求，相关人员正在寻求有效的解决方案来应对和克服日益严重的全球癌症负担，从而推动了市场的发展。

限制全球癌症生物疗法市场的因素

癌症治疗方法带来的高昂经济负担严重阻碍了全球癌症生物疗法市场的扩张。这些治疗方法费用高昂，尤其对于经济欠发达地区和农村地区的患者而言，限制了他们获得可能挽救生命的治疗的机会。这项经济挑战极大地限制了市场的覆盖范围，迫使许多患者因经济拮据而选择疗效较差或替代治疗方法。因此，整个市场发展面临挑战，难以为更广泛的患者群体提供必要的治疗。

全球生物癌症治疗市场趋势

在全球基因组学和分子生物学进步的推动下，癌症生物疗法市场正经历着向个人化和标靶治疗的显着转变。随着人们对肿瘤独特的遗传和分子特征了解的不断深入，针对特定基因异常和生物标记的生物疗法的研发日益重要。这种个人化治疗能够改善患者预后，最大限度地减少副作用，并提高疗效。透过针对肿瘤生长和发展过程中涉及的潜在分子机制，这些创新治疗方法正在革新癌症治疗，实现对各种癌症类型的更精准、更有效的管理，从而重塑肿瘤治疗格局。

目录

介绍

• 调查目标
• 市场定义和范围

调查方法

• 调查过程
• 二手资料和一手资料方法
• 市场规模估算方法
• 市场假设与限制

执行摘要

• 全球市场展望
• 主要市场亮点
• 细分市场概览
• 竞赛概况

市场动态与展望

• 总体经济指标
• 驱动因素和机会
• 限制与挑战
• 供给面趋势
• 需求面趋势
• 波特的分析和影响

关键市场考察

• 关键成功因素
• 市场影响指数
• 关键投资机会
• 市场吸引力指数
• 市场生态系统
• PESTEL 分析
• 监管环境
• 案例研究分析
• 价值链分析
• 专利分析
• 技术分析
• 临床试验分析
• 疾病流行病学

全球癌症生物疗法市场规模（按治疗方法类型划分）（2019-2032 年）

• 单株抗体
  • 裸单株抗体
  • 偶联单株抗体
  • 双特异性单株抗体
• 癌症疫苗
  • 预防性疫苗
  • 治疗性疫苗
• 细胞激素疗法
  • 白细胞介素
  • 干扰素
• 过继性细胞移植
  • CAR-T细胞疗法
  • 肿瘤浸润淋巴细胞
  • TCR疗法
• 免疫查核点抑制剂
  • PD-1/PD-L1抑制剂
  • CTLA-4抑制剂
• 标靶癌症生长抑制剂
  • 蛋白酪氨酸激酶抑制剂（TKIs）
  • 蛋白酶体抑制剂（PIs）
  • mTOR抑制剂
• 血液细胞生长因子（BCGF）
  • 来诺格拉司亭
  • Filgrastim
  • 其他 BCGF
• 溶瘤病毒疗法
• 基因治疗
• 其他治疗方法

全球癌症生物疗法市场规模（按癌症类型划分）（2019-2032 年）

• 肺癌
• 乳癌
• 大肠直肠癌
• 摄护腺癌
• 白血病
• 胰臟癌
• 卵巢癌
• 其他癌症类型

全球癌症生物疗法市场按给药途径划分（2019-2032 年）

• 静脉注射
• 皮下注射
• 瘤内给药
• 口服
• 其他的

全球癌症生物疗法市场规模（按分销管道划分）（2019-2032 年）

• 网路药房
• 零售药房
• 医院药房

全球癌症生物疗法市场规模（2019-2032 年）

• 北美（治疗方法、癌症类型、给药途径、通路划分）
  • 美国
  • 加拿大
• 欧洲（治疗方法、癌症类型、给药途径、通路划分）
  • 英国
  • 德国
  • 西班牙
  • 法国
  • 义大利
  • 其他欧洲地区
• 亚太地区（依治疗方法、癌症类型、给药途径、分销管道划分）
  • 中国
  • 印度
  • 日本
  • 韩国
  • 亚太其他地区
• 拉丁美洲（依治疗方法、癌症类型、给药途径、分销管道划分）
  • 巴西
  • 墨西哥
  • 其他拉丁美洲地区
• 中东和非洲（按治疗方法、癌症类型、给药途径、分销管道划分）
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争对手仪錶板

• 前五大公司对比
• 主要企业的市场定位（2025 年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市占率分析（2025 年）

主要企业简介

• Pfizer Inc.
• The following companies are listed for indicative purposes only. Similar information will be provided for each, with detailed financial data available exclusively for publicly listed companies.
• Merck & Co.
• Bristol Myers Squibb
• F. Hoffmann-La Roche Ltd
• Novartis AG
• AstraZeneca
• Amgen Inc.
• Eli Lilly and Company
• Sanofi
• AbbVie Inc.
• GlaxoSmithKline Plc.
• Bayer AG
• Exelixis Inc.
• Incyte
• BioNTech SE
• Adaptimmune
• Nanobiotix
• Vir Biotechnology Inc.
• Innate Pharma Inc.
• AdcentrX Therapeutics

结论和分析师建议

Global Cancer Biological Therapy Market size was valued at USD 108.5 Billion in 2024 and is poised to grow from USD 116.42 Billion in 2025 to USD 204.56 Billion by 2033, growing at a CAGR of 7.3% during the forecast period (2026-2033).

The global market for cancer biological therapy is set to expand significantly, driven by the increasing incidence of cancer and the proliferation of specialized treatment facilities. Experts are innovating with nanotechnology to develop advanced therapeutic solutions, creating opportunities for personalized cancer care. The emphasis on biological therapies and the integration of nanotechnology present transformative potential for cancer treatment, allowing for more tailored and effective patient outcomes. As research and technological advancements continue to progress in this field, the market for cancer biological therapy is poised for remarkable growth, enhancing efforts in the ongoing battle against cancer and improving the overall landscape of cancer care globally.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Cancer Biological Therapy market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Cancer Biological Therapy Market Segments Analysis

Global Cancer Biological Therapy Market is segmented by Therapy Type, Cancer Type, Route of Administration, Distribution Channel and region. Based on Therapy Type, the market is segmented into Monoclonal Antibodies, Cancer Vaccines, Cytokine Therapy, Adoptive Cell Transfer, Immune Checkpoint Inhibitors, Targeted Cancer Growth Blockers, Blood Cell Growth Factors (BCGF), Oncolytic Virus Therapy, Gene Therapy and Other Therapy Types. Based on Cancer Type, the market is segmented into Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Leukemia, Pancreatic Cancer, Ovarian Cancer and Other Cancer Types. Based on Route of Administration, the market is segmented into Intravenous (IV), Subcutaneous, Intratumoral, Oral and Others. Based on Distribution Channel, the market is segmented into Online Pharmacies, Retail Pharmacies and Hospital Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Cancer Biological Therapy Market

The escalating incidence of cancer across the globe significantly propels the expansion of the global cancer biological therapy market. The rise in cases, particularly of Small Cell Lung Cancer (SCLC), predominantly affects individuals in their sixties to eighties, highlighting a pressing healthcare challenge. The substantial mortality associated with SCLC and the prevalence of lung cancer as a leading cause of cancer-related deaths further underline the urgent need for innovative treatment options. These factors create a heightened demand for cancer biological therapies, as stakeholders seek effective solutions to manage and combat the growing cancer burden worldwide, thereby driving the market's progress.

Restraints in the Global Cancer Biological Therapy Market

The high financial burden linked to cancer treatment methods creates a notable obstacle for the expansion of the Global Cancer Biological Therapy market. The elevated costs of these therapies can be prohibitive, particularly for individuals in economically disadvantaged or rural regions, limiting their access to potentially life-saving treatments. This affordability issue significantly restricts the market's reach, as numerous patients may opt for less effective or alternative remedies due to financial constraints. Consequently, this challenges the overall development of the market and hampers its ability to provide necessary therapies to a broader population in need.

Market Trends of the Global Cancer Biological Therapy Market

The global cancer biological therapy market is experiencing a significant trend towards personalized and targeted treatment modalities, driven by advancements in genomics and molecular biology. As the unique genetic and molecular characteristics of tumors become increasingly well-documented, the development of biological therapies tailored to address specific genetic abnormalities and biomarkers has gained prominence. This customization leads to improved patient outcomes, minimized side effects, and enhanced therapeutic efficacy. By concentrating on the underlying molecular mechanisms responsible for tumor growth and proliferation, these innovative therapies are revolutionizing cancer treatment, enabling more precise and effective management of various cancer types, thereby reshaping the therapeutic landscape in oncology.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impact Factor
• Top Investment Pockets
• Market Attractiveness Index
• Market Ecosystem
• PESTEL Analysis
• Regulatory Landscape
• Case Study Analysis
• Value Chain Analysis
• Patent Analysis
• Technology Analysis
• Clinical Trial Analysis
• Disease Epidemiology

Global Cancer Biological Therapy Market Size by Therapy Type (2019-2032)

• Market Overview
• Monoclonal Antibodies
  • Naked MAB
  • Conjugated MAB
  • Bispecific MAB
• Cancer Vaccines
  • Preventive Vaccines
  • Therapeutic Vaccines
• Cytokine Therapy
  • Interleukins
  • Interferons
• Adoptive Cell Transfer
  • CAR T-cell therapy
  • Tumor-Infiltrating Lymphocytes
  • TCR therapy
• Immune Checkpoint Inhibitors
  • PD-1/PD-L1 inhibitors
  • CTLA-4 inhibitors
• Targeted Cancer Growth Blockers
  • Tyrosine Kinase Inhibitors (TKIs)
  • Proteasome Inhibitors (PIs)
  • mTOR Inhibitors
• Blood Cell Growth Factors (BCGF)
  • Lenograstim
  • Filgrastim
  • Other BCGF
• Oncolytic Virus Therapy
• Gene Therapy
• Other Therapy Types

Global Cancer Biological Therapy Market Size by Cancer Type (2019-2032)

• Market Overview
• Lung Cancer
• Breast Cancer
• Colorectal Cancer
• Prostate Cancer
• Leukemia
• Pancreatic Cancer
• Ovarian Cancer
• Other Cancer Types

Global Cancer Biological Therapy Market Size by Route of Administration (2019-2032)

• Market Overview
• Intravenous (IV)
• Subcutaneous
• Intratumoral
• Oral
• Others

Global Cancer Biological Therapy Market Size by Distribution Channel (2019-2032)

• Market Overview
• Online Pharmacies
• Retail Pharmacies
• Hospital Pharmacies

Global Cancer Biological Therapy Market Size (2019-2032)

• North America (By Therapy Type, By Cancer Type, By Route of Administration, & By Distribution Channel)
  • US
  • Canada
• Europe (By Therapy Type, By Cancer Type, By Route of Administration, & By Distribution Channel)
  • UK
  • Germany
  • Spain
  • France
  • Italy
  • Rest of Europe
• Asia-Pacific (By Therapy Type, By Cancer Type, By Route of Administration, & By Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia Pacific
• Latin America (By Therapy Type, By Cancer Type, By Route of Administration, & By Distribution Channel)
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa (By Therapy Type, By Cancer Type, By Route of Administration, & By Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Dashboard

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025

Key Company Profiles

• Pfizer Inc.
  • Company Overview
  • Product Portfolio Overview
  • Financial Overview
  • Key Developments
• The following companies are listed for indicative purposes only. Similar information will be provided for each, with detailed financial data available exclusively for publicly listed companies.
• Merck & Co.
• Bristol Myers Squibb
• F. Hoffmann-La Roche Ltd
• Novartis AG
• AstraZeneca
• Amgen Inc.
• Eli Lilly and Company
• Sanofi
• AbbVie Inc.
• GlaxoSmithKline Plc.
• Bayer AG
• Exelixis Inc.
• Incyte
• BioNTech SE
• Adaptimmune
• Nanobiotix
• Vir Biotechnology Inc.
• Innate Pharma Inc.
• AdcentrX Therapeutics

Conclusion & Analyst Recommendations